-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DtFSlSs/M/hT3j1kwPt2tItq6cj6sb+y4E7MB0CujIW50Dz7mgE+JcbRqiw7Eld4 nOcMN2BeWXTQGlDDwQTUcA== 0000851909-07-000026.txt : 20070802 0000851909-07-000026.hdr.sgml : 20070802 20070801181207 ACCESSION NUMBER: 0000851909-07-000026 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070802 DATE AS OF CHANGE: 20070801 GROUP MEMBERS: ISRAEL A. ENGLANDER GROUP MEMBERS: MILLENCO, L.P. GROUP MEMBERS: MILLENNIUM MANAGEMENT, L.L.C. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AUXILIUM PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001182129 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 233016883 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79973 FILM NUMBER: 071017349 BUSINESS ADDRESS: STREET 1: 40 VALLEY STREAM PARKWAY CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 484 321 5900 MAIL ADDRESS: STREET 1: 40 VALLEY STREAM PARKWAY CITY: MALVERN STATE: PA ZIP: 19355 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MILLENNIUM PARTNERS, L.P. CENTRAL INDEX KEY: 0000851909 IRS NUMBER: 133521699 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: C/O MILLENNIUM MANAGEMENT, L.L.C. STREET 2: 666 FIFTH AVE CITY: NEW YORK STATE: NY ZIP: 10103 BUSINESS PHONE: 2128414000 MAIL ADDRESS: STREET 1: C/O MILLENNIUM MANAGEMENT, L.L.C. STREET 2: 666 FIFTH AVE CITY: NEW YORK STATE: NY ZIP: 10103 FORMER COMPANY: FORMER CONFORMED NAME: MILLENNIUM PARTNERS L P DATE OF NAME CHANGE: 20000628 SC 13D/A 1 auxl_sc13d-a1.htm Schedule 13D



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D
Under the Securities Exchange Act of 1934

(Amendment No. 1)

Auxilium Pharmaceuticals, Inc.
(Name of Issuer)

Common Stock, par value $0.01 per share
(Title of Class of Securities)

05334D1077
(CUSIP Number)

Simon M. Lorne, Esq.
Millennium Management, L.L.C.
666 Fifth Avenue, 8th Floor
New York, New York 10103
(212) 841-4100
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

July 31, 2007
(Date of event which requires filing of this statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g) check the following box o .

SCHEDULE 13D

CUSIP No. 05334D1077
1
NAMES OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

Millennium Partners, L.P.
13-3521699
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)   o
(b)   þ
3
SEC USE ONLY
4
SOURCE OF FUNDS

WC, OO
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

  þ
6
CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
7
SOLE VOTING POWER

-0-
8
SHARED VOTING POWER

400,000 
9
SOLE DISPOSITIVE POWER

-0- 
10
SHARED DISPOSITIVE POWER

400,000 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

400,000
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 

 o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

1.0%
14
TYPE OF REPORTING PERSON

PN

SCHEDULE 13D

CUSIP No. 05334D1077
1
NAMES OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

Millenco, L.L.C.
13-3532932
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)   o
(b)   þ
3
SEC USE ONLY
4
SOURCE OF FUNDS

WC, OO
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

  þ
6
CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
7
SOLE VOTING POWER

-0-
8
SHARED VOTING POWER

2,500,000 
9
SOLE DISPOSITIVE POWER

-0- 
10
SHARED DISPOSITIVE POWER

2,500,000 
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,500,000
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES 

 o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

6.3%
14
TYPE OF REPORTING PERSON

OO, BD

SCHEDULE 13D

CUSIP No. 05334D1077
1
NAMES OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

Millennium Management, L.L.C.
13-3804139
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)   o
(b)   þ
3
SEC USE ONLY
4
SOURCE OF FUNDS

WC, OO
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

  þ
6
CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
7
SOLE VOTING POWER

-0-
8
SHARED VOTING POWER

2,900,000 
9
SOLE DISPOSITIVE POWER

-0- 
10
SHARED DISPOSITIVE POWER

2,900,000 

11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,900,000

12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
 o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

 7.3%
14
TYPE OF REPORTING PERSON

OO

SCHEDULE 13D

CUSIP No. 05334D1077
1
NAMES OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).

Israel A. Englander
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)   o
(b)   þ
3
SEC USE ONLY
4

SOURCE OF FUNDS


WC, OO
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

þ

6
CITIZENSHIP OR PLACE OF ORGANIZATION

United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
 7
SOLE VOTING POWER

-0-

8
SHARED VOTING POWER
2,900,000 
9
SOLE DISPOSITIVE POWER
 
-0- 
10
SHARED DISPOSITIVE POWER

2,900,000 

11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
2,900,000
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
 o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
7.3%
14
TYPE OF REPORTING PERSON
 
IN

Explanatory Note  

Introduction

   This Amendment No. 1 to Schedule 13D ("Amendment No. 1 to Schedule 13D") amends the Schedule 13D filed on September 27, 2006 ("Schedule 13D") by the Reporting Persons, relating to their beneficial ownership of the Common Stock (as defined in Item 1, below) of Auxilium Pharmaceuticals, Inc. (the "Issuer").

   This Amendment No. 1 (i) amends and restates Item 2, Item 3, Item 5 and Item 6 and (ii) reflects a material change since the filing of Schedule 13D in the number of shares beneficially owned by Millenco, L.L.C. (and that may be deemed to be beneficially owned by certain of the other Reporting Persons) and the percentage ownership of the Issuer’s Common Stock represented by Millenco, L.L.C.’s ownership of such shares. Except for the above-referenced amendments, Amendment No. 1 does not modify any of the information previously reported on the Schedule 13D.

Item 1.      Security and Issuer.

   The name of the Issuer is Auxilium Pharmaceuticals, Inc., a Delaware corporation. The address of the Issuer’s offices is 40 Valley Stream Parkway, Malvern, Pennsylvania, 19355. This Amendment No. 1 to Schedule 13D relates to the Issuer’s common stock, par value $0.01 per share (the "Common Stock").

Item 2.      Identity and Background.

   (a)-(c), (f).  This statement is being filed by Millennium Partners, L.P., a Cayman Islands exempted limited partnership ("Millennium Partners") and Millenco, L.L.C., a Delaware limited liability company ("Millenco") (formerly known as Millenco, L.P.). Millenco is a broker-dealer and a member of the American Stock Exchange and the NASDAQ. Millennium Management, L.L.C., a Delaware limited liability company ("Millennium Management"), is the managing partner of Millennium Partners and the manager of Millenco, and consequently may be deemed to have voting control and investment discretion over securities owned by Millennium Partners and by Millenco. Israel A. Englander ("Mr. Englander") is the managing member of Millennium Management. As a result, Mr. Englander may be deemed to be the beneficial owner of any shares deemed to be beneficially owned by Millennium Management. The foregoing should not be construed in and of itsel f as an admission by Millennium Management or Mr. Englander as to beneficial ownership of the shares owned by Millennium Partners or by Millenco.

   The business address for Millennium Partners, Millenco, Millennium Management and Mr. Englander is c/o Millennium Management, L.L.C., 666 Fifth Avenue, New York, New York 10103. Mr. Englander is a United States citizen.

   Note:  Integrated Holding Group, L.P., a Delaware limited partnership ("Integrated Holding Group"), is a non-managing member of Millenco. As a non-managing member, Integrated Holding Group has no investment or voting control over Millenco or its securities positions.

   (d)  During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

   (e)  On December 1, 2005, Millennium Management and Mr. Englander, together with Millennium Partners and certain related persons and entities, entered into settlements with the Securities and Exchange Commission ("SEC") and the Attorney General of the State of New York (the "NYAG") relating to allegations that Millennium Partners had engaged in a pattern of deceptive "market timing" of mutual fund shares in years prior to 2004 and, in the case of the settlement with the NYAG only, had failed to take adequate steps to prevent a trader from engaging in mutual fund "late trading" in violation of firm policy. The parties neither admitted nor denied the allegations or findings (except as to jurisdiction) but consented to the entry of findings. The SEC proceedings are In the Matter of Millennium Partners, L.P., et al. Securities Act Release No. 8639 (December 1, 2005), available at www.sec.gov. Contemporaneously, the NYAG issu ed an Assurance of Discontinuance relating to the claims and findings of that office.

   Neither the Reporting Persons nor any other party admitted or denied any of the allegations or findings in these matters. The remedies included disgorgement by the entities of approximately $148 million of mutual fund trading profits, civil penalties aggregating approximately $32.15 million (with approximately $30 million being paid by Mr. Englander), an administrative order to cease and desist from violations of the antifraud provisions of the Securities Act and the Securities Exchange Act, and prophylactic relief.

Item 3.      Source and Amount of Funds or Other Consideration.

   Pursuant to a subscription agreement dated as of September 14, 2006 between the Issuer and Millennium Partners, Millennium Partners expended $3,400,000 in a private placement to acquire 400,000 shares of Common Stock. The amount of funds used to purchase the remaining 2,500,000 shares held by Millenco was approximately $27,989,900, calculated on an average cost basis (excluding brokerage commissions) by account. Millennium Partners and Millenco effect purchases of securities primarily through margin accounts maintained for them with prime brokers, which may extend margin credit to Millennium Partners and Millenco as and when required to open or carry positions in the margin accounts, subject to applicable Federal margin regulations, stock exchange rules and the prime broker’s credit policies. In such instances, the positions held in the margin accounts are pledged as collateral security for the repayment of debit balances in the accounts.

Item 4.       Purpose of Transaction.

   The Reporting Persons are engaged in the investment business. In pursuing this business, the Reporting Persons analyze the operations, capital structure and markets of companies, including the Issuer, on a continuous basis through analysis of documentation and discussions with knowledgeable industry and market observers and with representatives of such companies (often at the invitation of management). From time to time, one or more of the Reporting Persons may hold discussions with third parties or with management of such companies in which the Reporting Persons may suggest or take a position with respect to potential changes in the operations, management or capital structure of such companies as a means of enhancing shareholder value. Such suggestions or positions may relate to one or more of the transactions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Exchange Act, including, without limitation, such matters as disposing of or selling all or a portion of the company or acquiring another company or business, changing operating or marketing strategies, adopting or not adopting certain types of anti-takeover measures and restructuring the Issuer’s capitalization or dividend policy.

   The Reporting Persons employ the services of a number of portfolio managers, each of whom independently employs a separate and distinct trading strategy. A portion of the securities of the Issuer held by the Reporting Persons are held in accounts of the Reporting Persons managed by portfolio managers who engage in event-, risk- or merger-arbitrage or fundamental strategies.

   Except as set forth above, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions required to be described in Item 4 of Schedule 13D. Each of the Reporting Persons may, at any time, review or reconsider its position with respect to the Issuer and formulate plans or proposals with respect to any of such matters, but has no present intention of doing so.

Item 5.      Interest in Securities of the Issuer.

   (a)  As of the date hereof, (i) Millennium Partners is the beneficial owner of 400,000 shares of Common Stock and (ii) Millenco is the beneficial owner of 2,500,000 shares of Common Stock.

   Millennium Management, as the managing partner of Millennium Partners and the manager of Millenco, may also be deemed to beneficially own the above-described shares of Common Stock beneficially owned by Millennium Partners and Millenco, respectively.

   Mr. Englander, as the managing member of Millennium Management, may also be deemed to beneficially own the above-described shares of Common Stock beneficially owned by Millennium Partners and Millenco, respectively.

   The foregoing should not be construed in and of itself as an admission by Millennium Management or Mr. Englander as to beneficial ownership of the shares held by Millennium Partners and Millenco.

   Accordingly, as of the date of this filing, Mr. Englander and Millennium Management may be deemed to be beneficial owners of 2,900,000 shares of Common Stock which represents approximately 7.3% of the outstanding shares of Common Stock. The calculation of the foregoing percentage is on the basis of 39,929,188 shares of Common Stock outstanding as of June 30, 2007, as disclosed in the Issuer’s prospectus supplement filed pursuant to Rule 424(b)(5), dated June 7, 2007.

   (b)  Millennium Partners may be deemed to hold shared power to vote and to dispose of the 400,000 shares of Common Stock described in (a) above. Millenco may be deemed to hold shared power to vote and to dispose of the 2,500,000 shares of Common Stock described in (a) above. Mr. Englander and Millennium Management may be deemed to hold shared power to vote and to dispose of the 2,900,000 shares of Common Stock described in (a) above. The foregoing should not be construed in and of itself as an admission by Mr. Englander or Millennium Management as to beneficial ownership of the shares held by Millennium Partners and Millenco.

   (c)  Transactions in Common Stock during the past 60 days: Schedule A annexed hereto lists all transactions in the Common Stock during the past 60 days by the Reporting Persons. All transactions in the Common Stock were effected by Millenco in the open market.

   (d)  No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of, dividends from, or proceeds from the sale of, the shares of Common Stock reported in this Statement.

Item 6.      Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

   In connection with arrangements with its prime brokers, such prime brokers are permitted to lend securities in Millenco’s and Millennium Partners’ accounts (as the case may be) to the extent permitted by debit balances in such account. Millenco and Millennium Partners (as the case may be) generally will not have any knowledge of the specific loans made by such prime brokers. In addition, in the ordinary course of business, Millenco and/or Millennium Partners, as applicable (or its prime brokers), may borrow securities to satisfy delivery obligations arising from short sales. Millenco may also lend securities to third parties and such loans generally may be recalled upon demand.

   There are no other contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.

Item 7.      Material to Be Filed as Exhibits.

   Exhibit I:  Joint Filing Agreement, dated as of July 31, 2007, by and among Millennium Partners, L.P., Millenco, L.P., Millennium Management, L.L.C. and Israel A. Englander.

SIGNATURE

   After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: July 31, 2007

MILLENNIUM PARTNERS, L.P.

By: Millennium Management, L.L.C.
       its managing partner

By: /s/ David Nolan

Name: David Nolan
Title:  Co-President

 

MILLENCO, L.L.C.

By: /s/ Mark Meskin

Name: Mark Meskin
Title:  Chief Executive Officer

 

MILLENNIUM MANAGEMENT, L.L.C.

By: /s/David Nolan

Name: David Nolan
Title:  Co-President

 

/s/ Israel A. Englander by Simon Lorne
pursuant to Power of Attorney filed with
the SEC on June 6, 2005

Israel A. Englander


EXHIBIT I

JOINT FILING AGREEMENT

    This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.01 per share, of Auxilium Pharmaceuticals, Inc., a Delaware corporation, is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated: July 31, 2007

MILLENNIUM PARTNERS, L.P.

By: Millennium Management, L.L.C.
       its managing partner

By: /s/ David Nolan

Name: David Nolan
Title:  Executive Vice President

 

MILLENCO, L.L.C.

By: /s/ Mark Meskin

Name: Mark Meskin
Title:  Chief Executive Officer

 

MILLENNIUM MANAGEMENT, L.L.C.

By: /s/David Nolan

Name: David Nolan
Title:  Executive Vice President

 

/s/ Israel A. Englander by Simon Lorne
pursuant to Power of Attorney filed with
the SEC on June 6, 2005

Israel A. Englander


Schedule A

Transactions in the Issuer’s Common Stock during the past 60 days:

Date of Transaction Quantity Purchased
(Sold)		 Price Per Share
$
7/31/2007 4 17.93
7/31/2007 20 17.92
7/31/2007 23 17.79
7/31/2007 24 17.91
7/31/2007 32 17.79
7/31/2007 52 17.83
7/31/2007 76 17.92
7/31/2007 96 17.93
7/31/2007 100 17.64
7/31/2007 100 17.66
7/31/2007 100 17.67
7/31/2007 100 17.67
7/31/2007 100 17.68
7/31/2007 100 17.68
7/31/2007 100 17.68
7/31/2007 100 17.69
7/31/2007 100 17.705
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.715
7/31/2007 100 17.75
7/31/2007 100 17.75
7/31/2007 100 17.75
7/31/2007 100 17.76
7/31/2007 100 17.76
7/31/2007 100 17.76
7/31/2007 100 17.76
7/31/2007 100 17.76
7/31/2007 100 17.76
7/31/2007 100 17.76
7/31/2007 100 17.78
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.79
7/31/2007 100 17.8
7/31/2007 100 17.8
7/31/2007 100 17.8
7/31/2007 100 17.8
7/31/2007 100 17.8
7/31/2007 100 17.8
7/31/2007 100 17.8
7/31/2007 100 17.83
7/31/2007 100 17.83
7/31/2007 100 17.83
7/31/2007 100 17.83
7/31/2007 100 17.83
7/31/2007 100 17.83
7/31/2007 100 17.83
7/31/2007 100 17.83
7/31/2007 100 17.83
7/31/2007 100 17.83
7/31/2007 100 17.83
7/31/2007 100 17.86
7/31/2007 100 17.86
7/31/2007 100 17.86
7/31/2007 100 17.86
7/31/2007 100 17.86
7/31/2007 100 17.9
7/31/2007 100 17.9
7/31/2007 100 17.9
7/31/2007 100 17.9
7/31/2007 100 17.9
7/31/2007 100 17.91
7/31/2007 100 17.915
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.93
7/31/2007 100 17.93
7/31/2007 100 17.93
7/31/2007 100 17.93
7/31/2007 100 17.93
7/31/2007 100 17.93
7/31/2007 100 17.93
7/31/2007 100 17.93
7/31/2007 100 17.93
7/31/2007 100 17.93
7/31/2007 100 17.94
7/31/2007 100 17.95
7/31/2007 100 17.95
7/31/2007 100 17.95
7/31/2007 100 17.95
7/31/2007 100 17.96
7/31/2007 100 17.98
7/31/2007 100 17.98
7/31/2007 100 17.98
7/31/2007 100 17.98
7/31/2007 100 17.98
7/31/2007 100 17.98
7/31/2007 101 17.83
7/31/2007 180 17.92
7/31/2007 200 17.71
7/31/2007 200 17.71
7/31/2007 200 17.71
7/31/2007 200 17.79
7/31/2007 200 17.8
7/31/2007 200 17.8
7/31/2007 200 17.92
7/31/2007 200 17.92
7/31/2007 200 17.94
7/31/2007 200 17.94
7/31/2007 200 17.94
7/31/2007 200 17.98
7/31/2007 200 17.98
7/31/2007 300 17.69
7/31/2007 300 17.71
7/31/2007 300 17.71
7/31/2007 300 17.94
7/31/2007 345 17.79
7/31/2007 400 17.83
7/31/2007 400 17.98
7/31/2007 700 17.71
7/31/2007 700 17.715
7/31/2007 700 17.715
7/31/2007 700 17.785
7/31/2007 900 17.83
7/31/2007 1,000 17.79
7/31/2007 1,300 17.71
7/31/2007 1,300 17.8
7/31/2007 1,300 17.95
7/31/2007 1,800 17.8
7/31/2007 1,800 17.96
7/31/2007 2,000 17.71
7/31/2007 10,000 17.93
7/31/2007 350,000 17.93
7/31/2007 200,000 17.9089
7/31/2007 3 17.59
7/31/2007 20 17.71
7/31/2007 20 17.72
7/31/2007 27 17.72
7/31/2007 29 17.7
7/31/2007 29 17.7
7/31/2007 29 17.7
7/31/2007 37 17.72
7/31/2007 39 17.71
7/31/2007 48 17.65
7/31/2007 53 17.72
7/31/2007 63 17.72
7/31/2007 68 17.71
7/31/2007 71 17.7
7/31/2007 71 17.7
7/31/2007 71 17.7
7/31/2007 80 17.72
7/31/2007 97 17.59
7/31/2007 100 17.55
7/31/2007 100 17.55
7/31/2007 100 17.55
7/31/2007 100 17.55
7/31/2007 100 17.55
7/31/2007 100 17.55
7/31/2007 100 17.55
7/31/2007 100 17.56
7/31/2007 100 17.58
7/31/2007 100 17.59
7/31/2007 100 17.59
7/31/2007 100 17.59
7/31/2007 100 17.59
7/31/2007 100 17.59
7/31/2007 100 17.59
7/31/2007 100 17.6
7/31/2007 100 17.6
7/31/2007 100 17.62
7/31/2007 100 17.62
7/31/2007 100 17.64
7/31/2007 100 17.64
7/31/2007 100 17.64
7/31/2007 100 17.64
7/31/2007 100 17.64
7/31/2007 100 17.64
7/31/2007 100 17.64
7/31/2007 100 17.64
7/31/2007 100 17.64
7/31/2007 100 17.64
7/31/2007 100 17.64
7/31/2007 100 17.64
7/31/2007 100 17.64
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.65
7/31/2007 100 17.68
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.7
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.71
7/31/2007 100 17.715
7/31/2007 100 17.72
7/31/2007 100 17.72
7/31/2007 100 17.72
7/31/2007 100 17.72
7/31/2007 100 17.72
7/31/2007 100 17.72
7/31/2007 100 17.72
7/31/2007 100 17.72
7/31/2007 100 17.72
7/31/2007 100 17.72
7/31/2007 100 17.72
7/31/2007 100 17.72
7/31/2007 100 17.77
7/31/2007 100 17.78
7/31/2007 100 17.83
7/31/2007 100 17.83
7/31/2007 100 17.84
7/31/2007 100 17.84
7/31/2007 100 17.84
7/31/2007 100 17.845
7/31/2007 100 17.89
7/31/2007 100 17.9
7/31/2007 100 17.92
7/31/2007 100 17.92
7/31/2007 100 17.925
7/31/2007 100 17.93
7/31/2007 100 17.93
7/31/2007 100 17.93
7/31/2007 100 17.93
7/31/2007 100 17.93
7/31/2007 100 17.93
7/31/2007 100 17.93
7/31/2007 100 17.93
7/31/2007 100 17.96
7/31/2007 100 17.96
7/31/2007 100 17.965
7/31/2007 100 17.97
7/31/2007 100 17.97
7/31/2007 100 18
7/31/2007 100 18
7/31/2007 100 18
7/31/2007 100 18.08
7/31/2007 100 18.09
7/31/2007 100 18.34
7/31/2007 100 18.345
7/31/2007 102 17.72
7/31/2007 200 17.56
7/31/2007 200 17.58
7/31/2007 200 17.65
7/31/2007 200 17.65
7/31/2007 200 17.65
7/31/2007 200 17.65
7/31/2007 200 17.7
7/31/2007 200 17.7
7/31/2007 200 17.7
7/31/2007 200 17.705
7/31/2007 200 17.72
7/31/2007 200 17.72
7/31/2007 200 17.72
7/31/2007 200 17.72
7/31/2007 200 17.84
7/31/2007 200 17.87
7/31/2007 200 17.87
7/31/2007 200 17.91
7/31/2007 200 17.965
7/31/2007 200 17.98
7/31/2007 200 17.98
7/31/2007 200 18.345
7/31/2007 300 17.65
7/31/2007 300 17.7
7/31/2007 300 17.72
7/31/2007 300 17.72
7/31/2007 300 17.77
7/31/2007 300 17.92
7/31/2007 300 17.93
7/31/2007 300 17.965
7/31/2007 300 17.97
7/31/2007 300 18.09
7/31/2007 352 17.65
7/31/2007 400 17.56
7/31/2007 400 17.56
7/31/2007 400 17.64
7/31/2007 400 17.7
7/31/2007 400 17.7
7/31/2007 400 17.7
7/31/2007 400 17.7
7/31/2007 400 17.7
7/31/2007 400 17.705
7/31/2007 400 17.705
7/31/2007 400 17.705
7/31/2007 400 17.705
7/31/2007 400 17.71
7/31/2007 400 17.72
7/31/2007 400 17.72
7/31/2007 400 17.72
7/31/2007 400 17.72
7/31/2007 400 17.72
7/31/2007 400 17.72
7/31/2007 400 17.89
7/31/2007 400 17.91
7/31/2007 400 17.92
7/31/2007 400 17.93
7/31/2007 400 17.95
7/31/2007 400 17.95
7/31/2007 400 17.96
7/31/2007 400 17.98
7/31/2007 400 18
7/31/2007 500 17.65
7/31/2007 500 17.65
7/31/2007 500 17.87
7/31/2007 500 17.92
7/31/2007 500 17.92
7/31/2007 500 17.925
7/31/2007 500 17.965
7/31/2007 500 18
7/31/2007 600 17.55
7/31/2007 600 17.62
7/31/2007 600 17.7
7/31/2007 600 17.925
7/31/2007 600 17.96
7/31/2007 600 17.96
7/31/2007 700 17.7
7/31/2007 700 17.7
7/31/2007 700 17.71
7/31/2007 700 17.92
7/31/2007 700 17.92
7/31/2007 700 17.97
7/31/2007 750 17.72
7/31/2007 800 17.56
7/31/2007 800 17.925
7/31/2007 800 17.925
7/31/2007 800 17.925
7/31/2007 800 17.955
7/31/2007 800 17.965
7/31/2007 800 17.965
7/31/2007 800 17.98
7/31/2007 900 17.72
7/31/2007 900 17.92
7/31/2007 900 17.97
7/31/2007 1,000 17.68
7/31/2007 1,000 17.93
7/31/2007 1,000 17.95
7/31/2007 1,100 17.96
7/31/2007 1,100 17.965
7/31/2007 1,300 17.705
7/31/2007 1,300 18.215
7/31/2007 1,500 17.72
7/31/2007 1,547 17.56
7/31/2007 1,600 17.92
7/31/2007 1,600 17.925
7/31/2007 1,741 17.71
7/31/2007 1,900 17.96
7/31/2007 2,200 17.96
7/31/2007 2,200 17.965
7/31/2007 2,600 17.96
7/31/2007 2,800 17.95
7/31/2007 2,800 17.95
7/31/2007 2,800 17.96
7/31/2007 3,200 17.925
7/31/2007 4,000 18.215
7/31/2007 4,600 17.68
7/31/2007 5,600 18.215
7/31/2007 5,600 18.215
7/31/2007 6,300 17.955
7/31/2007 6,900 17.93
7/31/2007 10,000 17.72
7/31/2007 10,000 17.965
7/31/2007 10,000 18.215
7/31/2007 11,200 18.215
7/31/2007 15,000 17.775
7/31/2007 22,300 18.215

Note: All of the above transactions were effected by Millenco, L.L.C. in the open market.

-----END PRIVACY-ENHANCED MESSAGE-----